Jump to content

Pemtumomab

From Wikipedia, the free encyclopedia
Pemtumomab
Monoclonal antibody
Type?
SourceMouse
TargetMUC1
Clinical data
Trade namesTheragyn
Routes of
administration
Intraperitoneal
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
 ☒NcheckY (what is this?)  (verify)

Pemtumomab (trade name Theragyn) is a mouse monoclonal antibody used to treat cancer. The substance has affinity to various types of cancer, like ovarian cancer and peritoneal cancer, via the polymorphic epithelial mucin (PEM or MUC-1) and delivers the radioisotope Yttrium-90 into the tumour.[1] As of 2009, it is undergoing Phase III clinical trials.[2]

It has been granted orphan drug status in Europe.[3]

References

[edit]
  1. ^ Oei AL, Moreno M, Verheijen RH, Sweep FC, Thomas CM, Massuger LF, von Mensdorff-Pouilly S (October 2008). "Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer". International Journal of Cancer. 123 (8): 1848–53. doi:10.1002/ijc.23725. PMID 18661524. S2CID 2287723.
  2. ^ Clinical trial number NCT00004115 for "Monoclonal Antibody Therapy in Treating Patients With Ovarian Cancer or Primary Peritoneal Cancer in Remission Following Surgery and Chemotherapy" at ClinicalTrials.gov
  3. ^ Antisoma's Lead Product, Pemtumomab Granted European Orphan Drug Status[dead link]